BTK Degrader Bexobrutideg in Patients With Relapsed/Refractory CLL/SLL  

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
Second-line Pirtobrutinib in CLL/SLL After Covalent BTKi Treatment: A Pooled Analysis of BRUIN LOXO-BTK18001 and BRUIN CLL-321  

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
CaDAnCe-101 Phase I Study of the BTK Degrader BGB-16673 in R/R CLL/SLL  

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
BRUIN CLL-314: Pirtobrutinib vs Ibrutinib in Treatment-Naive and BTKi-Naive R/R CLL/SLL  

Content Format:

Video

Credit Type:

AMA

Credits:

0.25
Final Analysis of the Phase I/II BRUIN Trial of Pirtobrutinib in Patients With CLL/SLL Previously Treated with a Covalent BTKi    

Content Format:

Conference Coverage

Credit Type:

AMA

Credits:

0.25
ALPINE Long-term Extension Study of Zanubrutinib in Relapsed or Refractory CLL/SLL

Content Format:

Conference Coverage

Credit Type:

AMA

Credits:

0.25